Novel Antiplatelets in Development

CME-certified Monograph • CME-certified Webinar  

Release Date May 2008   Expiration Date May 2009

Instructions for Participation

To participate in each of these activities and obtain credit, please (1) review the CME information below and select "Begin Course" at the bottom of the page (2) view the webinar slides and/or the monograph and reflect on the content, (3) complete the appropriate post-test and evaluation, then submit.

Program Overview

Because platelets perform a key role in both thrombus and atherosclerotic plaque formation, antiplatelet therapy is critical treatment for managing patients with acute coronary syndromes (ACS). Limitations to current therapeutic options include modest levels of platelet inhibition, variability in response, slow rates of onset, and continued thrombotic and atherosclerotic events despite treatment.  Participants will learn and evaluate developments in new therapeutic targets on the platelet, as well as agents under investigation, and be able to apply this knowledge toward improving the care of patients with ACS.

Faculty David A. Morrow, MD, MPH  Brigham and Women's Hospital  Boston, Massachusetts

Learning Objectives

After participating in these activities, learners will be able to:  

Target Audience

These educational activities have been developed for physicians and other health care providers in primary care, cardiology, and emergency medicine who manage ischemic risk in patients with ACS in the acute, periprocedural, and chronic settings.

Accreditation Statement

INNOVIA Education Institute, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  

Designation Statement

INNOVIA Education Institute designates each of these educational activities for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activities.

Disclosure of Financial Relationships and Discussion of Off-label Uses

INNOVIA Education Institute adheres to standards and guidelines of the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating that those activities for which continuing education credits are awarded must be balanced, independent, objective, scientifically rigorous, and free from commercial bias. In accordance with the ACCME’s Standards for Commercial Support, INNOVIA Education Institute’s disclosure policy requires disclosure to activity participants of all relevant financial relationships of the planners, presenters, and authors involved in the development of CME content. “Relevant financial relationship” is defined as a financial relationship in any amount that has occurred within the last 12 months with a commercial interest whose products or services are discussed in the CME activity. Information about relevant financial relationships appears below:  

David A. Morrow, MD, MPH, has disclosed the following relevant financial relationships:  

He has received research grant support from Accumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman Coulter, Bristol-Myers Squibb, CV Therapeutics, Eli Lilly and Company, GlaxoSmithKline, Inotek Pharmaceuticals, Integrated Therapeutics, Merck and Company, Merck/Schering-Plough Joint Venture, Millennium Pharmaceuticals, Nanosphere, Novartis Pharmaceuticals, Nuvelo, Pfizer, Roche Diagnostics, sanofi-aventis, Sanofi-Synthelabo, Singulex, and Schering-Plough; received honoraria from Bayer Diagnostics, Beckman Coulter, CV Therapeutics, Dade-Behring, sanofi-aventis, and Roche Diagnostics. He has served on advisory boards for Beckman Coulter, Critical Diagnostics, Genentech, and OrthoClinical Diagnostics, and has served as a consultant to GlaxoSmithKline and sanofi-aventis.  

Content collaborators at INNOVIA Education Institute have disclosed that they have no relevant financial relationships.  

The peer reviewer for these activities, Dave Hager, MD, has disclosed that he has no relevant financial relationships.  

Uses of some pharmaceutical agents, medical devices, and other products identified in these activities may not be the same as those indicated in product labeling approved by the Food and Drug Administration. INNOVIA requires that any discussions of such “off-label” uses be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. The following faculty report discussion of off-label uses of pharmaceutical or medical device products in these activities: David A. Morrow, MD, MPH. 

INNOVIA Education Institute is committed to the free exchange of medical information in the interest of improvement in the quality and safety of patient care. Opinions, recommendations, and other discussions in these activities, including discussion of off-label uses, represent the independent views of the presenters/authors and not an endorsement by INNOVIA Education Institute.  

Acknowledgement of Learners’ Expectations

INNOVIA Education Institute, LLC, recognizes that you are a lifelong learner who has chosen to engage in continuing medical education (CME) to help maintain, improve, increase, or otherwise enhance your knowledge and skills in the practice of medicine. As part of INNOVIA’s duty to you as a learner, we acknowledge your right to expect that these CME activities include:  

Content that


An environment that


Disclosure of

We hope that these activities have fulfilled the expectations listed above. If it has not, please respond to that effect on the evaluation forms and include specific feedback to assist us with making improvements to future activities.

INNOVIA’s Policy on Privacy and Confidentiality

INNOVIA respects the privacy of participants in our CME activities. INNOVIA collects personal information (such as participants’ names, e-mail and mailing addresses, and phone and fax numbers) only when that information is specifically and knowingly provided by participants. This personal information is retained in a database by INNOVIA and is used specifically for the purposes of generating attendance certificates and maintaining participant records; it is not made available to the general public. INNOVIA may contact participants who provide personal information, but only for the purpose of collecting follow-up evaluation data or with their express permission (eg, affirmative response to a question asking whether participants would like to receive additional information or e-mailings).

If you have questions about the content of these activities or the submission of CME materials, please contact:

INNOVIA Education Institute, LLC.  
Attn: LK  
9722 Patuxent Woods Dr. Suite 200  
Columbia, MD 21046  

If you have technical difficulties, please contact technical support at support@coronaryinvaders.com.  

Program Sponsorship

---